#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2910	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2525	341.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1952	1952	T	415	T,C	368,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	2910	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2525	341.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1686	1686	C	389	C	322	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4890	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3956	369.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1818	1818	A	400	A	344	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4890	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3956	369.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2452	2452	C	415	C,A	362,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4890	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3956	369.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2526	2526	A	420	A,C	351,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4890	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3956	369.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3078	3078	C	467	C,A	392,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	500	folP	855	855	100.0	folP.l15.c4.ctg.1	2108	70.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1287	1289	AGC	101;101;101	A;G;C	79;82;77	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	920	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3902	70.5	1	SNP	p	S91F	1	.	.	271	273	TTC	855	857	TTC	70;70;70	T;T;C,A	59;59;60,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	920	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3902	70.5	1	SNP	p	D95G	1	.	.	283	285	GGC	867	869	GGC	71;70;70	G;G;C,A	60;59;55,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	920	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3902	70.5	1	SNP	p	G95N	0	.	.	283	285	GGC	867	869	GGC	71;70;70	G;G;C,A	60;59;55,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	420	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1783	70.6	1	SNP	p	G45D	0	.	.	133	135	GGC	709	711	GGC	116;115;115	G;G;C	103;101;102	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	268	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1417	56.6	0	.	n	.	0	A197.	DEL	197	197	A	811	811	A	105	A	95	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	918	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3236	84.6	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1612	1614	GTC	125;125;127	G;T;C	104;102;102	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	918	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3236	84.6	1	SNP	p	D86N	0	.	.	256	258	GAC	718	720	GAC	108;107;107	G,C;A,C;C	87,1;88,1;92	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	918	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3236	84.6	1	SNP	p	R87I	0	.	.	259	261	CGT	721	723	CGT	107;106;106	C,A;G;T	91,1;89;87	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	918	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3236	84.6	1	SNP	p	R87W	0	.	.	259	261	CGT	721	723	CGT	107;106;106	C,A;G;T	91,1;89;87	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	918	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3236	84.6	1	SNP	p	S87R	1	.	.	259	261	CGT	721	723	CGT	107;106;106	C,A;G;T	91,1;89;87	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	918	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3236	84.6	1	SNP	p	S88P	0	.	.	262	264	TCC	724	726	TCC	106;106;106	T,C;C;C	91,1;94;95	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	854	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3234	78.9	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1580	1582	TGC	113;112;112	T;G;C	92;94;92	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	854	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3234	78.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1790	1792	GGC	110;111;110	G;G;C	93;92;91	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	682	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2782	73.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1500	1502	GCA	102;103;102	G,T;C,G;A,C	85,1;82,1;82,1	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	682	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2782	73.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1503	1505	ATC	102;102;102	A,C;T;C	81,1;80;82	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	682	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2782	73.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1515	1517	GTG	105;105;105	G;T;G,C	84;81;82,1	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	682	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2782	73.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1515	1517	GTG	105;105;105	G;T;G,C	84;81;82,1	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	682	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2782	73.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2019	2021	ACC	89;88;87	A,C;C;C	68,1;75;75	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	682	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2782	73.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2073	2075	GCG	85;85;85	G;C,G;G	70;64,1;61	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	682	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2782	73.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2073	2075	GCG	85;85;85	G;C,G;G	70;64,1;61	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	682	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2782	73.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2196	2198	GGC	87;87;87	G;G,C;C,G	72;74,1;72,2	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	682	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2782	73.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2205	2207	GGC	83;83;83	G,C;G;C	68,1;70;71	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	682	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2782	73.2	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2223	2225	TCG	83;83;86	T,G;C;G	68,1;72;71	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	938	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3608	77.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1942	1944	CCG	73;74;73	C,G;C;G	58,1;60;54	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	490	porA	1146	1146	99.56	porA.l15.c4.ctg.1	2280	64.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	767	767	C	79	C	66	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	572	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2109	80.5	0	.	p	.	0	N38E	NONSYN	112	114	AAT	739	741	GAA	123;124;123	G;A;A	97;101;98	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	572	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2109	80.5	0	.	p	.	0	N134D	NONSYN	400	402	AAT	1027	1029	GAT	118;118;117	G;A;T	101;98;96	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	572	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2109	80.5	0	.	p	.	0	M141I	NONSYN	421	423	ATG	1048	1050	ATA	108;108;107	A,C;T,A;A,G	94,1;93,1;90,2	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	572	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2109	80.5	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1150	1152	TCA	102;103;102	T;C;A	89;89;86	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	572	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2109	80.5	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1279	1281	GTC	102;100;101	G,T;T;C	82,1;86;87	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	572	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2109	80.5	0	.	p	.	0	S295G	NONSYN	883	885	AGT	1510	1512	GGT	106;106;105	G,A;G;T	85,3;89;87	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	572	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2109	80.5	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1609	1611	GCA	106;107;106	G,T;C;A	94,1;95;91	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	572	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2109	80.5	1	SNP	p	G120K	1	.	.	358	360	AAG	985	987	AAG	123;123;123	A;A;G	100;99;102	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	572	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2109	80.5	1	SNP	p	A121D	1	.	.	361	363	GAC	988	990	GAC	124;125;125	G;A,C;C	105;104,1;101	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	572	porB1b	1047	1047	99.14	porB1b.l6.c4.ctg.1	2109	80.5	1	SNP	p	D121N	0	.	.	361	363	GAC	988	990	GAC	124;125;125	G;A,C;C	105;104,1;101	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1730	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5349	96.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2236	2238	AAT	99;99;100	A;A;T	89;88;86	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	324	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1502	64.7	1	SNP	p	V57M	1	.	.	169	171	ATG	727	729	ATG	134;134;134	A;T;G	118;118;119	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
